Maynard Um
-
-
-
-
-
-
-
Baird Downgrades Nuvalent (NUVL) to Neutral
-
-
-
-
-
-
-
Piper Sandler Downgrades Nuvalent (NUVL) to Neutral
-
-
-
-
-
-
-
Nuvalent (NUVL) Reiterated at Buy by Stifel on Ph1/2 ALKOVE-1 study Data
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Nuvalent (NUVL)
-
-
-
-
-
-
-
Nuvalent receives FDA acceptance for cancer drug application
-
-
-
-
-
-
-
Nuvalent (NUVL) PT Raised to $155 at H.C. Wainwright
-
-
-
-
-
-
-
Nuvalent schedules data release for lung cancer drug trial
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

